Denali Therapeutics Inc. (DNLI) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は South San Francisco, CA, アメリカ. 現CEOは Ryan J. Watts.
DNLI を有する IPO日 2017-12-08, 443 名の正社員, に上場 NASDAQ Global Select, 時価総額 $3.2B.
Denali Therapeutics Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutic candidates for neurodegenerative diseases. The company's pipeline includes several clinical-stage programs, such as BIIB122/DNL151, a LRRK2 inhibitor in Phase I/Ib trials for Parkinson's disease, DNL310 for Hunter syndrome, DNL343 for ALS, and SAR443122/DNL758 for cutaneous lupus erythematosus. Denali has established strategic collaborations with leading pharmaceutical and research institutions including Takeda, Genentech, Sanofi, and Harvard University to advance its antisense therapy platform and other neurodegenerative disease treatments. The company was incorporated in 2013 and operates under its current name since March 2015.
